Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.